Patents by Inventor Gregory Bird
Gregory Bird has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240100061Abstract: Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.Type: ApplicationFiled: September 14, 2023Publication date: March 28, 2024Applicants: The Board of Trustees of the Leland Stanford Junior University, Soneira Inc., P.B.C.Inventors: Nolan R. Williams, Ian Kratter, AnnaMarie Daniels, Gregory Bird
-
Publication number: 20240100062Abstract: Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.Type: ApplicationFiled: September 14, 2023Publication date: March 28, 2024Applicants: The Board of Trustees of the Leland Stanford Junior University, Soneira Inc., P.B.C.Inventors: Nolan R. Williams, John Philip Coetzee, Andrew Dedinas Geoly, AnnaMarie Daniels, Gregory Bird
-
Publication number: 20210094990Abstract: Provided herein are peptide-based therapeutics that target FOXP3 and methods of use thereof to decrease the immunosuppressive effects of Tregs and inhibit immune dysregulation, while sparring inhibition of activated cytotoxic T cells, for example, in the context of anti-tumor immune responses, autoimmunity, inflammatory conditions, etc.Type: ApplicationFiled: December 7, 2017Publication date: April 1, 2021Inventors: James LaBelle, Rachel Eclov, Gregory Bird, Loren D. Walensky
-
Publication number: 20210052655Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.Type: ApplicationFiled: September 1, 2020Publication date: February 25, 2021Inventors: Brian C. TURNER, Yosef REFAELI, Gregory A. BIRD
-
Patent number: 10786534Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.Type: GrantFiled: July 6, 2017Date of Patent: September 29, 2020Assignee: TAIGA BIOTECHNOLOGIES, INC.Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird
-
Patent number: 10716828Abstract: The invention provides composition and therapeutic, methods for modulating homeostatic pathways that are useful in treatment, and prevention of diabetes, diabetes associated disorders, metabolic disorders and cancer.Type: GrantFiled: May 2, 2008Date of Patent: July 21, 2020Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Nika N. Danial, Loren D. Walensky, Gregory Bird, Susan R. Korsmeyer
-
Patent number: 10487129Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.Type: GrantFiled: May 30, 2017Date of Patent: November 26, 2019Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Patent number: 10273290Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating the viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.Type: GrantFiled: September 21, 2017Date of Patent: April 30, 2019Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Patent number: 10272115Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.Type: GrantFiled: March 12, 2013Date of Patent: April 30, 2019Assignee: TAIGA BIOTECHNOLOGIES, INC.Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird
-
Patent number: 10087420Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.Type: GrantFiled: June 10, 2016Date of Patent: October 2, 2018Assignee: TAIGA BIOTECHNOLOGIES, INC.Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Bird
-
Publication number: 20180177827Abstract: The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.Type: ApplicationFiled: July 6, 2017Publication date: June 28, 2018Inventors: Brian C. TURNER, Yosef REFAELI, Gregory A. BIRD
-
Publication number: 20180037636Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating the viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.Type: ApplicationFiled: September 21, 2017Publication date: February 8, 2018Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Patent number: 9822165Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.Type: GrantFiled: June 18, 2010Date of Patent: November 21, 2017Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Publication number: 20170260248Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.Type: ApplicationFiled: May 30, 2017Publication date: September 14, 2017Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Gregory Bird
-
Patent number: 9695224Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.Type: GrantFiled: February 9, 2016Date of Patent: July 4, 2017Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Gregory Bird
-
Publication number: 20160355785Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.Type: ApplicationFiled: June 10, 2016Publication date: December 8, 2016Inventors: Brian Curtis TURNER, Yosef REFAELI, Gregory BIRD
-
Patent number: 9365825Abstract: Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.Type: GrantFiled: March 12, 2013Date of Patent: June 14, 2016Assignee: TAIGA BIOTECHNOLOGIES, INC.Inventors: Brian Curtis Turner, Yosef Refaeli, Gregory Bird
-
Publication number: 20160159876Abstract: The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.Type: ApplicationFiled: February 9, 2016Publication date: June 9, 2016Inventors: Loren D. Walensky, Gregory Bird
-
Patent number: 9296805Abstract: The present invention provides stably cross-linked insulionotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention.Type: GrantFiled: July 8, 2011Date of Patent: March 29, 2016Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. Walensky, Gregory Bird
-
Publication number: 20150164950Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.Type: ApplicationFiled: July 19, 2013Publication date: June 18, 2015Applicant: Taiga Biotechnologies, Inc.Inventors: Brian C. Turner, Yosef Refaeli, Gregory A. Bird